Medical

Cervical Cancer Drugs Market – Size, Share, Growth and Trends Analysis 2018–2026

Seattle, WA, Aug-12, 2018 — / True Industry News / —

Cervical cancer develops in women’s cervix, and mainly affects sexually active women aged between 30 and 45. Cervical cancer often shows no symptoms in early stages. However, the death rate of cervical cancer can be significantly reduced with use of Pap test (Papanicolaou test): a screening procedure which can detect the changes in the cervix before the cancer develops. There are different types of cervical cancer, out of which two main types are squamous cell cancer and adenocarcinoma.

For instance, in September 2017, U.S. Food and Drug Administration (FDA) approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer, which includes cervical, lung, brain, colorectal and kidney cancer. Mvasi is indicated for use in persistent, recurrent, or metastatic cervical cancer. In August 2014, U.S. FDA approved Genentech’s Avastin, which is bevacizumab solution for intravenous infusion in combination with paclitaxel for the treatment of persistent, recurrent, or metastatic cervical cancer.

Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1746

Increasing incidence of cervical cancer among the global population, rise in incidence of HIV in women, lack of awareness regarding the diagnosis for prevention of invasive cancer is expected to drive growth of the cervical cancer drugs market. Moreover, American cancer Society, in March 2018, funded around 22 grants for cervical cancer, which accounted for around US$ 9.3 million. The funding value is offered to a single or group of research, which includes a specific type of a cancer or area of cancer. For instance, according to Cancer Research UK, 2015 data findings, around 3,200 new cervical cancer cases were registered in the UK annually from 2013 to 2015.

Key Vendors of Cervical Cancer Drugs Market: Some of the key players operating in the cervical cancer drugs market include F. Hoffmann-La Roche Ltd., Hetero, GlaxoSmithKline, plc, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Pfizer, Inc., AstraZeneca plc, Allergan plc, Biocon Limited, Bristol-Myers Squibb Company, and Novartis AG. Key players operating in the market are focused on organic growth strategies, in order to enhance its market share and retain its competence in the market. For instance, in July 2014, MedImmune: a biologics research and development division of AstraZeneca entered into a clinical trial collaboration with Advaxis. According to the agreement, both companies conducted Phase I/II immunotherapy study to evaluate the safety and efficacy of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor: MEDI4736, in combination with Advaxis’ cancer immunotherapy vaccine: ADXS-HPV. These study is conducted to develop treatment for patients with advanced, recurrent or refractory Human Papillomavirus (HPV)-associated cervical cancer.

Cervical Cancer Drugs market report analyses the market potential for each geographical region based on the growth rate, macroeconomic parameters, consumer buying patterns, and market demand and supply scenarios.

Regions of Cervical Cancer Drugs market:

• Americas

• APAC

• EMEA

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1746

Purchase

In the end, the report makes some important proposals for a new project of Cervical Cancer Drugs Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2018-2026 global Cervical Cancer Drugs industry covering all important parameters.

Cervical Cancer Drugs driver

Cervical Cancer Drugs challenge

Cervical Cancer Drugs trend

By Cancer Type:Squamous Cell Cancer, Adenocarcinoma,.

By Drug Type: By Prevention, Cervarix, Gardasil 9, Recombinant Human Papillomavirus (HPV) Bivalent Vaccine, Recombinant Human Papillomavirus (HPV) Nonavalent Vaccine, Recombinant Human Papillomavirus (HPV) Quadrivalent Vaccine, Others,.

By Treatment:Avastin (Bevacizumab), Bevacizumab, Bleomycin, Blenoxane (Bleomycin),Others,.

By Distribution Channels: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies,.

By Geography: North America, Latin America, Europe, Asia Pacific, Middle East, Africa,.

Request TOC of the Report @ https://www.coherentmarketinsights.com/ongoing-insight/toc/1746

Tags

Leave a Reply

Your email address will not be published. Required fields are marked *

Close